Amgen partners with clinical-research organization on biosimilars

04/26/2012 | MedCityNews.com

Amgen and PRA, a clinical-research organization, agreed to collaborate in a series of late-stage trials to develop the former's biosimilar drugs. The deal makes PRA the exclusive provider of CRO services for Amgen's biosimilars.

View Full Article in:

MedCityNews.com

Published in Brief: